Skip to main content

The outcome of COVID-19 among the geriatric age group in African countries: protocol for a systematic review and meta-analysis



According to the World Health Organization (WHO), the outbreak of coronavirus disease in 2019 (COVID-19) has been declared as a pandemic and public health emergency that infected more than 5 million people worldwide at the time of writing this protocol. Strong evidence for the outcome of COVID-19 among the geriatric age group has not been published in Africa. Therefore, this protocol will be served as a guideline to conduct a systematic review and meta-analysis of the outcome of COVID-19 among the geriatric age group in Africa.


Published and unpublished studies on the outcome of COVID-19 among the geriatric age group in Africa and written in any language will be included. Databases (PubMed / MEDLINE, Google Scholar, Google, EMBASE, Web of Science, Microsoft Academic, WHO COVID-19 database, Cochran Library, Africa Wide Knowledge, and Africa Index Medicus) from March to August 2020 will be searched. Two independent reviewers will select, screen, extract data, and assess the risk of bias. The proportion will be measured using a random-effects model. Subgroup analysis will be conducted to manage heterogeneity. The presence of publication bias will be assessed using Egger’s test and visual inspection of the funnel plots. This systematic and meta-analysis review protocol will be reported per the PRISMA-P guidelines.


This systematic review and meta-analysis protocol will be expected to quantify the outcome of COVID-19 among the geriatric age group in Africa.

Systematic review registration

This protocol was submitted for registration with the International Prospective Register of Systematic Reviews (PROSPERO) in April 2020 and accepted with the registration number: ( CRD42020180600.


Coronavirus disease 2019 (abbreviated “COVID-19”) is an infectious respiratory illness caused by a novel coronavirus, first identified in Wuhan, China, in December 2019. It is a large class of viruses that have been relatively widespread all across the world. The virus has low pathogenicity and high transmissibility capacity [1]. The Chinese authorities in Wuhan City, the capital of the province of Hubei, China, first announced this at the end of December 2019 [2,3,4,5]. After originating in Wuhan China last December 2019, COVID-19 has spread to at least 200 countries and region. The coronavirus disease 2019 (COVID-19) outbreak was declared a public health emergency of international concern by the World Health Organization (WHO) [6]. According to the WHO, the outbreak of coronavirus disease in 2019 (COVID-19) has been a pandemic that infected more than 5 million people at the time of writing this protocol and caused more than 324,000 deaths and 1.7 million recoveries worldwide within the 6 months duration [7]. Of the total cases, 15% develop severe disease, including pneumonia, and 5% become critically ill with respiratory failure, septic shock, and/or multi-organ failure [8].

The geriatric age groups were the most vulnerable age group and the Wuhan virus killing mostly the elderly. Of the 70- to 79-year-olds infected with coronavirus there, 8% have died. Among the over-80s, the case fatality rate is 15% [9].

A modeling study in Africa, classifying African countries as having high risk with 13 top WHO highest priority (Egypt, Algeria, and South Africa), moderate risk (Nigeria, Ethiopia, Morocco, Sudan, Angola, Tanzania, Ghana, and Kenya) and all other countries had low to moderate importation risk. The fatality rate of COVID in north African countries expected to be 11.02% [10, 11].

Generally speaking, African countries have poor health systems and this remains a source of concern, particularly in the event of an increase in outbreaks [12]. Due to this reason at the end of the pandemic, Africa might have some of the worst consequences of this COVID-19 pandemic.

In the WHO Africa region alone 83,000 to 190, 000 people could die of COVID-19 and 29 million to 44 million could get infected in the first year of the pandemic if nt measurement will not be taken. The research, which is based on prediction modeling, looks at 47 countries in the WHO African Region with a total population of 1 million. There would be an estimation of 3.6 to 5.5 million COVID-19 hospitalizations, of those 82,000 to 167,000 would be severe cases requiring oxygen, and 52,000 to 107,000 would be critical cases requiring breathing support [13].

There were different reports regarding the COVID-19 [14,15,16] but; there are no pooled results regarding the outcome of COVID-19 among the geriatric age group in Africa. Therefore, this study protocol will be guided to conduct a systematic review and meta-analysis of the outcome of COVID-19 among the geriatric age group in Africa.


Protocol registration

This review is registered in PROSPERO International Prospective Register of Systematic Reviews (CRD42020180600) ( and reported according to Preferred Reporting Items for Systematic reviews and MetaAnalysis protocol (PRISMA-P) guidelines [17] (Table 1).

Table 1 PRISMA-P (Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol

Search strategy and data extraction

The search strategy has been applied using Online Databases (PubMed / MEDLINE, Google Scholar, Google, EMBASE, Web of Science, Microsoft Academic, WHO COVID-19 database, Cochran Library, Africa Wide Knowledge, and Africa Index Medicus) from March to August 2020(Table 2). During the PROSPERO registration, a total of 10 articles were identified. The search terms which shall be used: “Wuhan coronavirus” OR “COVID-19” OR “novel coronavirus” OR “2019-nCoV” OR “coronavirus disease” OR “SARS-CoV-2” OR “SARS2” OR “severe acute respiratory syndrome coronavirus 2” OR” admission” OR” Burden” OR “Outcome”. Other searching terms will be used “mortality” OR “prevalence” OR” incidence” OR” cardiovascular complications” OR” Geriatrics Age Group” OR” renal complications” “hematological complications of COVID-19” OR”prevalence of asymptomatic, mild, moderate and severe cases” OR “admission” (“number admitted to specialized units or intensive care units” OR” outcome” (“number of infected patients OR” “number of recoveries” OR” case fatality rate” OR “number of cured patients readmitted” OR “long term complications” such as chronic heart failure, cardiac arrhythmias, and recurrent thromboembolic diseases.

Table 2 Searching strategy

Searching results will be independently evaluated by two different reviewers. The literature search technique will be developed using the headings of the medical subject headings (Mesh), BOOLEAN (AND/OR) operator will be used.

The blinding will be maintained by using the Royyan that allows/ obligates each reviewer to work without knowing the other reviewer’s choice. This review will be created using the metadata of the “COVID-19 Open Research Dataset” ( (updated May 2020). We only uploaded the metadata (reference) file of 63 k + coronavirus and COVID-19 research articles with links to PubMed, Microsoft Academic, and the WHO COVID-19 database of publications. We had to transform the metadata file (using to make it compatible with Rayyan. r.

Selection and data collection process

Data will be Extracted using the predefined standardized extraction form. Full texts for the eligible titles and/or abstracts including those where there is uncertainty will be obtained for further assessment on whether to include in the study or not. Where necessary, authors will be contacted for additional information to confirm eligibility of studies. The agreement between review authors will be measured using Cohen’s κ statistic. Reasons for excluding articles will be recorded.

Where there is missing information, the corresponding author of the study will be contacted to request the missing information. A maximum of three emails will be sent to the corresponding author to request for additional information before excluding the study. For studies appearing in more than one published article, we will consider the most recent, comprehensive, and with the largest sample size. For surveys appearing in one article with multiple surveys conducted at different time points, we shall treat each survey as a separate study. For multi-national studies, data will be separated to show the estimate at the country level.

Data extracted comprised information about the month of publication, country, and design of the study, admission rate, burden, outcome, diagnostic criteria, comorbidity, COVID-19, mean age,ethnicity, sex (male proportion), signs and symptoms, complications, prevalence and/or incidence, and risk factors.

Inclusion and exclusion criteria

Studies presented as original articles studies that assessed outcomes from COVID-19 will be included.

Types of studies

Observational studies (including cross-sectional, case-control, and cohort) and the randomized controlled trial will be included. In the case of duplicate reports, the most comprehensive and up-to-date version will be taken into account.


All Patients from 65 years old or more, who are African residence and will be diagnosed as having COVID-19.


Demographic, clinical, laboratory, management, and outcome data will be reviewed.


Epidemiological data, mortality, and clinical outcomes of COVID-19. Establishing the clinical and epidemiological features, outcomes of COVID-19.


Hospital-based studies.

Publication date

March to August 2020.


All published and unpublished papers (thesis, manuscript, pre-print pending to be published, the report from WHO, uCommunicable Diseases Control, United Nations, and health authorities in different African countries) without the restriction of language will include in our review.

Method of diagnosis

No restriction on methods of diagnosis but we will conduct subgroup analysis based on diagnostic tools. WHO interim guidance and /or any WHO-recommended diagnostic criteria will be considered [18] (Table 3).

Table 3 Laboratory testing for coronavirus disease (COVID-19) in suspected human cases: interim guidance

Exclusion criteria

Studies that did not explain the criteria for the level COVID-19 outcome; studies that didn’t state the number of patients with COVID-19 will be excluded. Studies not performed in humans, qualitative studies, studies that lack relevant data needed to compute the outcome will be excluded. Experimental studies, letters, reviews, commentaries, editorials, case reports, or case series will be not included.

Quality assessment and risk of bias in individual studies

To assess the risk of bias and quality of studies included in this review, a tool developed by Hoy et al. for prevalence studies will be used [19] The tool contains 11 items; items 1–4 assess the external validity, 5–10 assess the internal validity, and item 11 is a summary of the overall risk by the reviewer based on the responses of the above 10 items which are scored 1 if yes and 0 if no. Studies will be classified as having a low (> 8), moderate or high (≤ 5) risk of bias. Additional file 1 shows this in more detail regarding the checklist of bias measurement on the observational study. For RCTs, we will use the SPIRIT 2013 Checklist [20]. Additional file 2 shows this in more detail regarding the checklist of SPIRIT.

Data management

A tool has been developed a priori to conduct the searching strategy and this will help to guide the screening and selection process. The tool will be piloted and revised before data extraction begins. First the search results will be uploaded to EndNote software and then duplicates will be removed.

Data items

The extraction form will be includes data on general information, authors, month, country, and region, type of publication, study characteristics (study design, setting, sample size, response rate, mean or median age, or age range), the outcome.


The outcome of COVID − 19 among the geriatric age group in Africa.

Data synthesis, analysis, and presentation

The data will be analyzed using the R software; V.3.5.3. All analyses will be performed using a “metaprop” routine using R version 3.5.3 for Windows [18]. Results will be reported as proportions with corresponding 95% confidence intervals (CIs). Forest plots will be drawn to visualize the combined outcome of COVID-19 and the extent of statistical heterogeneity between studies. Statistical heterogeneity will be assessed using theχ2 test on Cochrane’s Q statistic, 20 and quantified by calculating the I2 statistic (with values of 25, 50, and 75% is representative of the low, medium, and high heterogeneity, respectively) [19]. There will be a clinical heterogeneity between studies included in this study. The random-effects will be used to estimate the overall pooled outcome of COVID-19 in Africa. The presence of publication bias will be assessed using Egger’s test and funnel plots [20]. P-value < 0.10 on the Egger’s test will be considered statistically significant for publication bias. Moreover, other relevant findings will be summarized in a narrative format.

The crude numerators and denominators from the individual studies will be used to recalculate the study-specific outcome of COVID-19. The outcome estimates will be summarized by African geographic regions.

A meta-analysis will be performed on variables that are similar across the included studies.

A subgroup analyses will be performed based on the countries where the study conducted, diagnostic method they used, based on their ethnic background (African origin and -non-African ethnic origin). The inter-rater agreements between the researchers involved in study selection and those involved in the identification of risk of bias will be assessed using κ Cohen’s coefficient.


This systematic review and meta-analysis will be presented per the PRISMA checklist guidelines [14]. The PRISMA flow diagram will be used to record the different phases of the review process [14] (Fig. 1).

Fig. 1

Flow chart diagram will be shown the selection of articles for systemic review and meta-analysis of the outcome of COVID-19 among the geriatric age group in Africa

The summary will be used to display the data on the distribution of COVID-19 by variables of interest such as gender, residence, setting, and person-level characteristics. Funnel plots will be used to visualize publication bias of the included studies. Forest plots will be used to estimates the outcome of COVID-19 among the geriatric age group in Africa for the included studies as an overall pooled estimate for Africa. Results from this review will inform healthcare providers on the outcome of COVID − 19, hence providing evidence will bring the required changes needed in clinical practice and will support healthcare services in line with patients’ needs. Findings from this review will be shared in conferences, peer-review journals, and social media platforms.


This systematic review and meta-analysis will be expected to quantify the outcome of COVID-19 among the geriatric age group in Africa to guide policies and interventions.

Availability of data and materials

The datasets used and/or analyses during the study will be presented within the manuscript and available from the corresponding author on reasonable request.



Preferred Reporting Items for Systematic reviews and Meta-Analysis protocol


World Health Organization


Coronavirus Disease in 2019


  1. 1.

    Jiang S, Shi Z, Shu Y, Song J, Gao GF, Tan W, Guo D. A distinct name is needed for the new coronavirus. Lancet (London, England). 2020;395(10228):949.

    CAS  Article  Google Scholar 

  2. 2.

    Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. 2019;16(1):1–22.

    CAS  Article  Google Scholar 

  3. 3.

    Sohrabi C, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surgery. 2020;76:71-6.

  4. 4.

    Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the diamond princess cruise ship, Yokohama, Japan, 2020. Eurosurveillance. 2020;25(10):2000180.

    Article  Google Scholar 

  5. 5.

    Ho CS, Chee CY, Ho RC. Mental health strategies to combat the psychological impact of COVID-19 beyond paranoia and panic. Ann Acad Med Singap. 2020;49(1):1–3.

    Google Scholar 

  6. 6.

    Al-Shamsi HO, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua ML, Hotte SJ, Meyers BM. A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: an international collaborative group. Oncologist. 2020;25(6):e936.

    CAS  Article  Google Scholar 

  7. 7.

    Harries AD, Martinez L, Chakaya JM. Monitoring the COVID-19 pandemic in sub-Saharan Africa: focusing on health facility admissions and deaths. Int J Tuberc Lung Dis. 2020;24(5):550–2.

    CAS  Article  Google Scholar 

  8. 8.

    Geldsetzer P. Use of rapid online surveys to assess People's perceptions during infectious disease outbreaks: a cross-sectional survey on COVID-19. J Med Internet Res. 2020;22(4):e18790.

    Article  Google Scholar 

  9. 9.

    Gilbert M, Pullano G, Pinotti F, Valdano E, Poletto C, Boëlle PY, d'Ortenzio E, Yazdanpanah Y, Eholie SP, Altmann M, Gutierrez B. Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study. Lancet. 2020;395(10227):871–7.

    CAS  Article  Google Scholar 

  10. 10.

    Daw MA, El-Bouzedi AH. Modelling the epidemic spread of COVID-19 virus infection in Northern African countries. Travel Med Infect Dis. 2020;35:101671.

  11. 11.

    Ohia C, Bakarey AS, Ahmad T. COVID-19 and Nigeria: putting the realities in context. Int J Infect Dis. 2020.

  12. 12.

    Tadesse DB, Gebremeskel GG, Asefa GG, Abay M, Demoz GT. The burden, admission, and outcome of COVID-19 in Africa: protocol for a systematic review and meta-analysis. Emerging Microbes Infect. 2020;9(1):1372–8.

    CAS  Article  Google Scholar 

  13. 13.

    Gupta M, Abdelmaksoud A, Jafferany M, Lotti T, Sadoughifar R, Goldust M. COVID-19 and economy. Dermatol Ther. 2020.

  14. 14.

    Hutton B, Catala-Lopez F, Moher D. The PRISMA statement extension for systematic reviews incorporating network meta-analysis: PRISMA-NMA. Med Clin (Barc). 2016;147(6):262–6.

    Article  Google Scholar 

  15. 15.

    Ferrari D, Motta A, Strollo M, Banfi G, Locatelli M. Routine blood tests as a potential diagnostic tool for COVID-19. Clin Chem Lab Med (CCLM). 2020;1 (ahead-of-print).

  16. 16.

    Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, Baker P, Smith E, Buchbinder R. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol. 2012;65(9):934–9.

    Article  Google Scholar 

  17. 17.

    Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin JA, Doré CJ. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–7.

    Article  Google Scholar 

  18. 18.

    Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Archives Public Health. 2014;72(1):39.

    Article  Google Scholar 

  19. 19.

    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003;327(7414):557–60.

    Article  Google Scholar 

  20. 20.

    Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997;315(7109):629–34.

    CAS  Article  Google Scholar 

Download references


Not applicable.


Not applicable.

Author information




DBT conceived and designed the initial study. All authors contributed to the conceptualization and design of the study. DBT drafted the initial protocol. DBT is the guarantor of the review. The author(s) read and approved the final manuscript.

Corresponding author

Correspondence to Degena Bahrey Tadesse.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Additional file 1.

Quality assessment checklist for prevalence studies (adapted from Hoy et al).

Additional file 2.

SPIRIT 2013 Checklist: Recommended items to address in a randomized controlled trial.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tadesse, D.B., Wahdey, S., Negash, M. et al. The outcome of COVID-19 among the geriatric age group in African countries: protocol for a systematic review and meta-analysis. asthma res and pract 6, 11 (2020).

Download citation


  • Africa
  • COVID-19
  • Geriatric
  • Outcome